YMAB - YmAbs Price-to-Revenue Multiple

Symbol and logo of brand YmAbs (YMAB)

Y-mAbs Therapeutics is developing targeted therapies for complex pediatric brain tumors, establishing industry standards. The high margins of approved biologics provide the operating leverage necessary to fund new research and development. A specialized antibody ecosystem and drug delivery patents eliminate the risk of clinics switching to generics. The price-to-sales ratio demonstrates the multiplier dynamics, where the 4.60 mark records this indicator.

YMAB Y-mAbs Therapeutics: P/S Multiple in the range 07/04/2022 - 09/27/2025

Metric breakdowns and analytics for YmAbs (YMAB)

- current quotes and average value forecast:
Market Price ymabs.com|YMAB - Consensus Target
- market capitalization statistics:
Market Capitalization YmAbs|YMAB - Total Company Value
- book capitalization data:
Accounting Value per Share Y-mAbs Therapeutics|YMAB - Book Capitalization|Market Capitalization to Book Value Ratio ymabs.com|YMAB - Company Total Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Y-mAbs Therapeutics|YMAB - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Y-mAbs Corp|YMAB - Company Total Debt|Debt to Net Assets Ratio YmAbs|YMAB - Company Long-Term Liabilities|Amount of Current Liabilities Y-mAbs Therapeutics|Intermediate Coverage Ratio ymabs.com
- business earnings and investment ratios data:
YMAB - Net Profit|Expected Net Profit Y-mAbs Therapeutics|YMAB - Price to Earnings Ratio|Future Price to Earnings Multiple Y-mAbs Therapeutics Inc|YMAB - PEG Multiple|EV/EBITDA Multiple YmAbs|YMAB - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Y-mAbs Therapeutics|YMAB - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months ymabs.com|YMAB - Net earnings per share growth this year|Earnings growth forecast for next year Y-mAbs Therapeutics
- issuer revenue and sales details:
YMAB - Company Sales|Company Projected Revenue Volume ymabs.com|YMAB - P/S Multiple|Market Cap to Expected Sales Ratio YmAbs
Summary company analytics:ymabs.com, YMAB
Product sample of Y-mAbs Therapeutics

Y-mAbs Therapeutics (YMAB) holds exclusive patent rights for rare oncology treatments, creating high market value for each unit of future sales. The market capitalization-to-annual revenue ratio, reflected through the price-to-sales trend, measures the premium investors are willing to pay for a protected business model, allowing for an assessment of the monetization efficiency of orphan drugs relative to the company's market value.

Who Y-mAbs Therapeutics competes with

ONC - Price to Sales|Halozyme - Market Cap to Revenue|Price-to-Revenue Multiple Revolution Medicines Inc|AAPG - Price-to-Revenue Ratio|CG Oncology Therapeutics (CGON) - Market Cap to Revenue|URGN: P/S Multiple|bicara.com (BCAX) - P/S Multiple|PSNL (Personalis) - P/S Multiple|Price-to-Revenue Ratio ERAS|Price-to-Revenue Ratio Delcath (DCTH)|Price-to-Revenue Coefficient Aura Corp|Candel Therapeutics, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ARAY|SLS: Market Cap to Revenue|Actuate Therapeutics Inc. - Market Cap to Sales Volume|CTOR: P/S Multiple|TuHURA Biosciences - Market Capitalization-to-Revenue Ratio|TARA (Protara Therapeutics) - P/S Multiple|Price to Sales fatetherapeutics.com FATE|Price-to-Revenue Ratio Aadi Bioscience Inc (WHWK)|TCRX (tscan.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple CSBR (Champions Oncology, Inc.)|P/S Multiple XBiotech Inc XBIT|CVM - Price-to-Revenue Ratio|Price-to-Sales Ratio OSTX|RADX: P/S Multiple|Price to Sales Artiva Biotherapeutics (ARTV)|Market Cap to Revenue ANL|P/S Multiple Veru Corporation|Market Cap to Revenue TPST (Tempest Therapeutics)|Market Cap to Sales Volume XLO|P/S Multiple RENB (Renovaro)|Price-to-Revenue Coefficient Mural Oncology PLC (MURA)|Kairos Pharma Inc - P/S Multiple|OnKure Therapeutics Inc (OKUR) - Market Cap to Revenue|w2.cytomed.sg (GDTC) - Price-to-Revenue Ratio|CRIS - Price-to-Revenue Coefficient|Market Cap to Revenue APLM|Price to Sales Tharimmune Inc THAR|Price-to-Revenue Ratio Advanced Biomed Inc (ADVB)|Market Cap to Revenue Genprex Inc GNPX|P/S Multiple CLDI (Calidi Biotherapeutics, Inc.)|P/S Multiple sunshinebiopharma.com SBFM|Xenetic Bio - P/S Multiple|SLRX: Price-to-Revenue Ratio|PPBT: P/S Multiple|Market Cap to Revenue American Oncology Network, Inc.|BGNE (BeiGene, Ltd.) - P/S Multiple|P/S Multiple checkpointtx.com|Price-to-Revenue Ratio Elevation Oncology (ELEV)|icadmed.com - Market Cap to Revenue Ratio|P/S Multiple IKNA (Ikena Oncology)|NTBL - Market Cap to Revenue|Viracta - P/S Multiple|Price to Sales morphosys.com|NAYA Biosciences Inc. (NAYA) - Price-to-Revenue Ratio|Ascentage Pharma Group International - Market Capitalization-to-Revenue Ratio